Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04BLE
|
|||
| Former ID |
DIB002541
|
|||
| Drug Name |
A-3309
|
|||
| Synonyms |
Elobixibat; ALBI-3309; Ileal bile acid transporter inhibitors, AstraZeneca; ASBT inhibitor (oral, chronic idiopathic constipation), Albireo; IBAT inhibitor (oral, chronic idiopathic constipation), Albireo; Apical sodium-dependent bile acid transporter inhibitor (oral, chronic idiopathic constipation), Albireo; IBAT inhibitors (1,5-benzothiazepine derivatives), AstraZeneca
Click to Show/Hide
|
|||
| Indication | Lipid metabolism disorder [ICD-11: 5C52.Z] | Phase 3 | [1] | |
| Company |
AstraZeneca plc
|
|||
| Structure |
 |
Download2D MOL |
||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Ileal sodium/bile acid cotransporter (SLC10A2) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Bile secretion | |||
| Reactome | Recycling of bile acids and salts | |||
| WikiPathways | Bile acid and bile salt metabolism | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01895543) Safety and Tolerability Extension Trial for Patients With Chronic Idiopathic Constipation. U.S. National Institutes of Health. | |||
| REF 2 | Elobixibat for the treatment of constipation. Expert Opin Investig Drugs. 2013 Feb;22(2):277-84. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.